BiotechTube
Milu Labs

Milu Labs

San Francisco, United States· Est.
milulabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Milu Labs is an early-stage, privately-held diagnostics company targeting significant gaps in women's health through two innovative technology platforms: exosome-based 'bio-fingerprinting' and integrated multiomics analysis. The company's lead program is a non-invasive diagnostic test for early prediction of preterm birth, a major global health challenge. Led by a team with strong backgrounds in healthcare investment, diagnostics commercialization, and global strategy, the company is positioned to develop and commercialize these technologies, initially focusing on the Asian market before expanding worldwide.

Women's HealthObstetrics

Technology Platform

Two complementary diagnostic platforms: 1) Exosome analysis for generating predictive 'bio-fingerprints' from body fluids, and 2) Integrated multiomics (proteome, transcriptome, epigenome, microbiome) analyzed with AI to produce actionable clinical results.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The significant unmet need in women's health diagnostics, particularly for conditions like preterm birth, presents a large and growing market.
The company's focus on the Asian healthcare market, which is expanding rapidly, provides a strategic entry point for global commercialization.
The flexible, platform-based nature of its technology allows for potential expansion into multiple diagnostic areas beyond the initial focus.

Risk Factors

The core technologies (exosome analysis, clinical multiomics) are complex and face significant technical and clinical validation hurdles before achieving regulatory approval.
Commercialization, especially in diverse Asian markets, requires navigating complex regulatory pathways and establishing reimbursement, which is challenging even with experienced leadership.
The company faces competition from other entities developing biomarkers for women's health conditions and must prove superior clinical utility to drive adoption.

Competitive Landscape

The competitive landscape for advanced women's health diagnostics is emerging but fragmented. Milu Labs competes with other biotech startups and academic groups exploring exosome and multiomics applications, as well as larger diagnostic companies with broader portfolios. Its key differentiators are the specific integration of its two platforms, its explicit Asia-first commercial strategy, and its leadership's direct experience in bringing complex diagnostics into the Chinese market.

More companies in Diagnostics & Precision Medicine →More companies in United States →